-
Mashup Score: 0Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin–unresponsive High-risk Non–muscle-invasive Bladder Cancer: SWOG S1605 - 9 month(s) ago
Systemic atezolizumab demonstrated modest efficacy in patients with bacillus Calmette-Guérin–unresponsive high-risk non–muscle-invasive bladder cancer who were ineligible for or declined radical cystectomy. However, this benefit must be balanced carefully with the risk of disease progression and treatment-related toxicity.
Source: www.europeanurology.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 4Société Internationale d'Urologie Journal - 12 month(s) ago
Société Internationale d’Urologie Journal (SIUJ) is an editorially independent journal owned by the Société Internationale d’Urologie and published online six times a year. SIUJ publishes original peer-reviewed research and review articles in all areas of urology.
Source: siuj.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @SIU_Journal: SIUJ’s latest edition is now available online! Read the May 2023 issue today: https://t.co/Z7vUtalTgK #openaccess #journal…
-
-
Mashup Score: 6Société Internationale d'Urologie Journal - 1 year(s) ago
Société Internationale d’Urologie Journal (SIUJ) is an editorially independent journal owned by the Société Internationale d’Urologie and published online six times a year. SIUJ publishes original peer-reviewed research and review articles in all areas of urology.
Source: siuj.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @SIU_Journal: SIUJ’s latest edition is now available online! Read the January 2023 issue today: https://t.co/Z7vUtalTgK #openaccess #jo…
-
-
Mashup Score: 6Vanier Scholars 2022 - Vanier Canada Graduate Scholarships - 1 year(s) ago
Abioye, Raliat University of Ottawa Plant And Animal Biology – Food Science And Technology Functional significance of phase-specific inhibition of islet amyloid polypeptide fibril formation by food-derived peptide motifs. …
Source: vanier.gc.caCategories: Hem/Oncs, Latest HeadlinesTweet-
Congratulations to @BlackDavidG for being named a Vanier Graduate Scholar by the Natural Sciences and Engineering Research Council of Canada (NSERC) for academic excellence, research potential and leadership! 👏🥂👏 https://t.co/pkyTbZqKmD https://t.co/4aQZPJwCxO
-
-
Mashup Score: 1DECIDE Survey — PRECISION Registry - 1 year(s) ago
Decision-making, Experience, and Confidence In Determining Genomic Evaluation: The DECIDE SurveyGenomic testing for PCA can encompass tumor tissue tests, plasma circulating tumor DNA (ctDNA) tests, and germline tests.Genomic testing can have significant variability in marker/variants tests, comprehensiveness of the test, variant reporting, and clinical application.To enhance the translational…
Source: PRECISION RegistryCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @ResearchWyatt: Involved with genomic testing in prostate cancer? Please take our survey https://t.co/W7YJor3xCe - it is for anyone in c…
-
-
Mashup Score: 2About CUA | Canadian Urological Association - 2 year(s) ago
The Canadian Urological Association (CUA) does not provide professional medical advice, diagnosis or treatment and cannot respond to requests for direct feedback, specific patient information or physician referrals. You should first always seek the advice of your urologist, physician and other qualified health provider with any questions regarding your…
Source: cua.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @CanUrolAssoc: 🟡Join us for this meeting!🟡 For more info, agenda and registration:https://t.co/zMHPD6Vo9j #CBForum22 @pcvblack @WesKasso…
-
-
Mashup Score: 0
We provide a precise definition of bacillus Calmette-Guérin–exposed non–muscle-invasive bladder cancer. In addition, we describe parameters for clinical trial design on the basis of expert consensus with the intent of promoting the development of novel therapeutics in this disease state.
Source: European UrologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Defining "BCG-exposed" disease state which lies between "BCG-naïve" and "BCG-unresponsive" high risk non-muscle invasive #bladdercancer - a framework for clinical trial design in this important patient population. @IBCG_BladderCA @UroDocAsh @MRoumiguie https://t.co/UjQKGxVdgP
-
-
Mashup Score: 7
The company spent all of 2021 telling investors that its treatment for bladder cancer was on the path toward approval.
Source: STATCategories: Latest Headlines, Oncologists1Tweet-
RT @UroDocAsh: Shocking, if true https://t.co/NiQzIBVIWs @daviesbj @pcvblack @garysteinbergmd @ArjunBalarMD @bcan_chisolm @statnews
-
The future of IO for treatment of BCG-unresponsive NMIBC lies in combination therapies, e.g. IO+CG0070/nado/N-803/etc. Link to manuscript: https://t.co/JZ4iCfg6zb